TRAIL-R2/TNFRSF10B: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It’s the GeneMedi’s summary page for Target/Biomarker Introduction of TRAIL-R2/TNFRSF10B. The page also collects GeneMedi’s different modalities and formats products for TRAIL-R2 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi’s target-insight database-GM ITD database, the TRAIL-R2 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

The protein encoded by this gene is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. Two transcript variants encoding different isoforms and one non-coding transcript have been found for this gene. [provided by RefSeq, Mar 2009]

Target ID

GM-T70067

Target Name

TRAIL-R2

Gene ID

8795

Gene Official Name

TNFRSF10B

Gene Alias

CD262, DR5, KILLER, KILLER/DR5, TRAIL-R2, TRAILR2, TRICK2, TRICK2A, TRICK2B, TRICKB, ZTNFR9

Protein Sub-location

Transmembrane Protein

Category

Therapeutics Target, Immuno-oncology Target, INN Index, Cytokine

Pre-made TRAIL-R2-specific INN-index biosimilar (antibody&conjugates)-Conatumumab, Tilogotamab, eftozanermin alfa, Drozitumab, Tigatuzumab, Benufutamab, Lexatumumab

Anti-TRAIL-R2 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Filters Sort results
Reset Apply
Cat No.
Products Name (INN Index)
INN Name
Previous Name
Target
Format
Order
Pre-Made Benufutamab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody
Benufutamab
NA
TNFRSF10B/TRAIL-R2
Whole mAb
Pre-Made Conatumumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody
Conatumumab
NA
TNFRSF10B/TRAIL-R2
Whole mAb
Pre-Made Drozitumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody
Drozitumab
NA
TNFRSF10B
Whole mAb
Pre-Made Lexatumumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody
Lexatumumab
NA
TNFRSF10B
Whole mAb
Pre-Made Tigatuzumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody
Tigatuzumab
NA
TNFRSF10B
Whole mAb
Pre-Made Tilogotamab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody
Tilogotamab
NA
TNFRSF10B
Whole mAb
Pre-Made Eftozanermin Alfa Biosimilar, Fusion Protein targeting TNFRSF10B/TRAIL-R2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting CD262/DR5/KILLER/KILLER/DR5
eftozanermin alfa
NA
TNFRSF10B
Fusion Protein

Anti-TR10B/ TRAIL-R2/ TNFRSF10B antibody for FACS & in-vivo assay| GMab

Pre-made anti-TRAIL-R2 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-TRAIL-R2 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Filters Sort results
Reset Apply
Cat No.
Antibody Name
Format
Classified by tag
Order
Anti-TRAIL-R2/TNFRSF10B monoclonal antibody
mab
FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody